A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity
Authors
Keywords
-
Journal
eLife
Volume 8, Issue -, Pages -
Publisher
eLife Sciences Publications, Ltd
Online
2019-11-19
DOI
10.7554/elife.50036
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NRF2 addiction in cancer cells
- (2018) Hiroshi Kitamura et al. CANCER SCIENCE
- Glutathione metabolism in cancer progression and treatment resistance
- (2018) Ankita Bansal et al. JOURNAL OF CELL BIOLOGY
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
- (2017) Marco Jost et al. MOLECULAR CELL
- Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
- (2017) Kyuho Han et al. NATURE BIOTECHNOLOGY
- Rationalizing combination therapies
- (2017) NATURE MEDICINE
- Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis
- (2017) Murat Cokol et al. Science Advances
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
- (2016) Shom Goel et al. CANCER CELL
- Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing
- (2016) Andrew L. Paek et al. CELL
- Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
- (2016) Boyang Zhao et al. CELL
- Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis
- (2016) Trevor M. Penning CHEMICAL RESEARCH IN TOXICOLOGY
- Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis
- (2016) Alfeu Zanotto-Filho et al. MOLECULAR CANCER THERAPEUTICS
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
- (2016) Marc Hafner et al. NATURE METHODS
- Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation
- (2016) Max A Horlbeck et al. eLife
- High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma
- (2015) Elena Sebastián et al. ANNALS OF HEMATOLOGY
- Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
- (2015) Hyo-eun C Bhang et al. NATURE MEDICINE
- A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging
- (2014) Marvin E. Tanenbaum et al. CELL
- Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
- (2014) Luke A. Gilbert et al. CELL
- Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
- (2014) Sarah K. Knutson et al. PLoS One
- CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
- (2013) Luke A. Gilbert et al. CELL
- The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
- (2013) A. Hunter Shain et al. PLoS One
- Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells
- (2013) M. Kampmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Genetic Screens in Human Cells Using the CRISPR-Cas9 System
- (2013) Tim Wang et al. SCIENCE
- High-Throughput Methods for Combinatorial Drug Discovery
- (2013) X. Sun et al. Science Translational Medicine
- Evolutionary dynamics of cancer in response to targeted combination therapy
- (2013) Ivana Bozic et al. eLife
- Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others
- (2013) Hideaki Kobayashi et al. Cancer Medicine
- Combinatorial drug therapy for cancer in the post-genomic era
- (2012) Bissan Al-Lazikani et al. NATURE BIOTECHNOLOGY
- Defining principles of combination drug mechanisms of action
- (2012) J. R. Pritchard et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of the coding genome of diffuse large B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE GENETICS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Doxorubicin pathways
- (2010) Caroline F. Thorn et al. Pharmacogenetics and Genomics
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists
- (2009) Eran Eden et al. BMC BIOINFORMATICS
- Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
- (2009) Sabrina L. Spencer et al. NATURE
- Synergistic drug combinations tend to improve therapeutically relevant selectivity
- (2009) Joseph Lehár et al. NATURE BIOTECHNOLOGY
- Drug interactions and the evolution of antibiotic resistance
- (2009) Pamela J. Yeh et al. NATURE REVIEWS MICROBIOLOGY
- Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial
- (2008) Josep-Maria Ribera et al. BRITISH JOURNAL OF HAEMATOLOGY
- Drug interactions modulate the potential for evolution of resistance
- (2008) J.-B. Michel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab
- (2007) Yasodha Natkunam et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started